Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1, First-in-Human Study of IK-930, an Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IK 930 (Primary)
  • Indications Haemangioendothelioma; Mesothelioma; Soft tissue sarcoma; Solid tumours
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Ikena Oncology

    • Most Recent Events

    • 13 Jun 2024 Status changed from discontinued to active, no longer recruiting.
    • 28 May 2024 According to an Ikena Oncology media release, based on a review of clinical data to date, available resources, and the Company's strategic priorities, the Company decided to discontinue development of IK-930. The IK-930 Phase 1 program will begin winddown activities; treatment will continue for patients enrolled to date who have derived benefit. The Company will seek strategic options for the program, including potential partners for development of IK-930 in combination with other targeted agent
    • 28 May 2024 Status changed from recruiting to discontinued, according to an Ikena Oncology media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top